Eli Lilly (LLY)
(Delayed Data from NYSE)
$818.93 USD
-10.81 (-1.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$818.93 USD
-10.81 (-1.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
6 Stocks to Prepare for a Global Economic Slowdown
by Swarup Gupta
A slowdown in Europe and the ongoing trade conflicts have been cited as the major reasons for the IMF's projection cuts.
J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018, leading to an increase in shares in pre-market trading. 2019 sales guidance falls short of expectations.
Company News For Jan 22, 2019
by Zacks Equity Research
Companies In The News Are: TIF,LLY,KSU,JBHT
Lilly Stops Lartruvo Promotion as Confirmatory Study Fails
by Zacks Equity Research
Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
by Zacks Equity Research
Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Here is Why Growth Investors Should Buy Lilly (LLY) Now
by Zacks Equity Research
Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.
Pacira's Study on Exparel Label Expansion Meets Endpoints
by Madhu Goel
Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.
Ligand (LGND) Takes a Hit on Citron's Negative Research Report
by Zacks Equity Research
Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.
Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings
by Zacks Equity Research
Shares of Kitov Pharma (KTOV) soar about 169% as the company's anti-cancer candidate, NT219 shows positive results.
Intrexon Signs Licensing Agreement with Next Green Wave
by Zacks Equity Research
Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.
6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019
by Zacks Equity Research
Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.
Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
by Zacks Equity Research
Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $114.68 in the latest trading session, marking a -1.29% move from the prior day.
5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.
Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why
by Zacks Equity Research
Puma Biotech's (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet
by Zacks Equity Research
Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
by Kinjel Shah
Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.
Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting
by Zacks Equity Research
Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo
Novartis' Crizanlizumab Gets Breakthrough Therapy Status
by Zacks Equity Research
Novartis's (NVS) crizanlizumab gets Breakthrough Therapy designation by the FDA for the prevention of VOCs in patients of all genotypes with SCD.
Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo
by Zacks Equity Research
Lilly (LLY) looks to acquire small cancer biotech, Loxo Oncology, to expand its pipeline into targeted cancer therapies.
Crowded Cancer Space Triggers Big M&A Deals: More in Store?
by Zacks Equity Research
Following two blockbuster merger and acquisition deals, a rise in M&A activity in the pharma space is likely led by consolidation in the cancer space.
Company News For Jan 8, 2019
by Zacks Equity Research
Companies In The News Are: LOXO,LLY,DLTR,PCG,MAT
4 Biotechs That Are Potential Buyouts Post Celgene Deal
by Ekta Bagri
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.